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Abstract
Aims/hypothesis Type 2 diabetes and obesity are associated
with increased risk of site-specific cancers. We have inves-
tigated whether metabolic alterations at the level of adipose-
derived differentiating cells may affect specific phenotypes
of breast cancer cells.
Methods Growth profiles of breast cancer cell lines were
evaluated in co-cultures with differentiated adipocytes or
their precursor cells and upon treatment with adipocyte
conditioned media. Production and release of cytokines
and growth factors were assessed by real-time RT-PCR
and multiplex-based ELISA assays.
Results Co-cultures with either differentiated mouse 3T3-
L1 or human mammary adipocytes increased viability of
MCF-7 cells to a greater extent, when compared with
their undifferentiated precursors. Adipocytes cultured in
25 mmol/l glucose were twofold more effective in promoting
cell growth, compared with those grown in 5.5 mmol/l
glucose, and activated mitogenic pathways in MCF-7 cells.
Growth-promoting action was also enhancedwhen adipocytes
were incubated in the presence of palmitate or oleate. Inter-
estingly, 3T3-L1 and human adipocytes released higher
amounts of keratinocyte-derived chemokine/IL-8, the protein
‘regulated upon activation, normally Texpressed, and secreted’
(RANTES), and IGF-1, compared with their precursor cells.
Their levels were reduced upon incubation with low glucose
and enhanced by fatty acids. Moreover, both undifferentiated
cells and differentiated adipocytes from obese individuals
displayed about twofold higher IGF-1 release and MCF-7
cell growth induction than lean individuals. Finally, inhi-
bition of the IGF-1 pathway almost completely prevented
the growth-promoting effect of adipocytes on breast cancer
cells.
Conclusions/interpretation IGF-1 release by adipocytes is
regulated by glucose and fatty acids and may contribute to
the control of cancer cell growth in obese individuals.
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Abbreviations
Adipo 3T3-L1 3T3-L1 adipocytes
AU Arbitrary units
bFGF Basic fibroblast growth factor
CM Conditioned medium
ER Oestrogen (estrogen) receptor
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ERK Extracellular signal-regulated kinase








MAPK Mitogen-activated protein kinase
MCP-1 Monocyte chemoattractant protein 1




PDGF Platelet-derived growth factor
PI3K Phosphatidylinositol 3-kinase
PKB/Akt Protein kinase B
RANTES Regulated upon activation normally T
expressed, and secreted
STAT Signal transducer and activator of
transcription
SVF Stromal vascular fraction
TBS Tris-buffered saline
VEGF Vascular endothelial growth factor
Introduction
It has recently become clear that obesity and type 2 diabe-
tes are associated with an increased frequency of many
cancers [1, 2]. For instance, increased adiposity is associ-
ated with an increased risk of several cancers [3]. Similar-
ly, epidemiological data link type 2 diabetes with an
increased incidence of multiple types of cancer, including
breast, colorectal, hepatocellular, endometrial and pancre-
atic malignancies [4, 5]. Both obesity and diabetes can also
lead to poorer treatment outcome and increase cancer-
related mortality rates [6–8].
The adipocyte may represent a candidate to integrate
energy and nutrient metabolism with cancer cell growth by
regulating cell functions through a complex network of
endocrine, paracrine and autocrine signals [9–11]. Indeed,
in addition to storing excess calories in the form of lipid,
adipose tissue is an active endocrine organ that can have far-
reaching effects on the physiology of other tissues [12]. It
has been shown that several hormones, growth factors and
cytokines are produced or generated in white adipose tissue
[13]. Recent interest has centred on the role of adipokines,
chiefly leptin and adiponectin, and inflammatory cytokines
[14]. However, all of the adipocyte factors may be envi-
sioned as contributing factors for cancer onset or progres-
sion [15]. Moreover, adipocytes are largely represented in
the microenvironment of several tumours, possibly provid-
ing a number of signals and resources to tumour cells.
The adipocyte represents one of the most abundant cell
types surrounding breast cancer cells and may prove to be a
key player in the stromal–ductal epithelial cell interactions
within the mammary microenvironment [16]. In this regard,
several in-vitro and in-vivo studies demonstrated that adi-
pocytes can directly influence breast tumour growth [17].
Obesity has been consistently shown to increase the rate
of breast cancer occurrence in postmenopausal women by
30–50% [11]. Studies of breast cancer mortality rates and
survival illustrate that adiposity is associated both with
poorer survival and increased likelihood of recurrence
among those with the disease, regardless of menopausal
status and after adjustment for disease stage and treatment.
Very obese women (BMI ≥40.0) have breast cancer death
rates that are three times higher than very lean (BMI<20.5)
women [3, 18]. Moreover, case–control and cohort studies
showed that women with diabetes may have a 20% in-
creased risk of breast cancer [19] and increased cancer-
related mortality rate [20].
Nevertheless, whether adipocyte-derived factors are di-
rectly involved in breast cancer onset or progression is still
poorly understood [21]. The effect on tumour phenotype of
metabolic alterations at the level of the adipose tissue is
also unclear.
Here, we show that adipocytes may integrate inputs from
the metabolic environment and promote growth of breast
cancer cells. Indeed, both glucose and fatty acids enhance
the ability of adipocytes to produce factors, including IL-8,
RANTES (regulated upon activation, normally T expressed,
and secreted) and IGF-1, involved in the control of cancer
cell phenotypes. Finally, both stromal vascular fraction
(SVF) cells and differentiated adipocytes from obese indi-
viduals release more IGF-1 than those from lean individuals,
suggesting that obesity per se may enhance breast cancer
cell growth.
Methods
Materials Media, sera and antibiotics for cell culture were
from Lonza (Basel, Switzerland). Antibodies against
phospho-Ser473 protein kinase B (PKB/Akt1), forms of ex-
tracellular signal-regulated kinase (ERK), signal transducer
and activator of transcription (STAT)3 and actin were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Phospho-Thr202/Tyr204 ERK and phospho-Tyr705
STAT3 antibodies were obtained from Cell Signaling Tech-
nology (Danvers, MA, USA). PKB/Akt antibody was from
Millipore (Billerica, MA, USA). Anti-leptin antibodies were
a generous gift from G. Matarese (CNR, Naples, Italy).
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
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(SDS-PAGE) reagents were from Bio-Rad (Hercules, CA,
USA). All the other chemicals were from Sigma-Aldrich (St
Louis, MO, USA).
Cell cultures MCF-7 (ERα positive) and MDA-MB-231
(ERα negative) human breast cancer cells and 3T3-L1
mouse fibroblasts were cultured in DMEM supplemented
with 10% fetal bovine serum (FBS) and 2 mmol/l glutamine,
100 IU/ml penicillin and 100 IU/ml streptomycin. Cultures
were maintained in a humidified atmosphere of 95% air and
5% CO2 at 37°C. 3T3-L1 differentiation was achieved as
previously described [22]. Human adipose tissue samples
were obtained from mammary adipose tissue and from
abdominal subcutaneous adipose tissue biopsies. In detail,
mammary adipose tissue specimens were obtained from
women (n012; age 25–63 years; BMI 24.2–29) undergoing
surgical mammary reduction. All women were otherwise
healthy and free from metabolic or endocrine diseases.
Abdominal adipose tissue was obtained from obese (n010;
age 45–65 years; BMI 30–35) and lean women (n010; age
32–60 years; BMI 20–25) by abdominal biopsy in the
periumbilical region under local anaesthesia (2% lidocaine).
Informed consent was obtained from every study participant
before the surgical procedure. This procedure was approved
by the ethical committee of the University of Naples. Adi-
pose tissue was digested with collagenase and then adipose-
derived SVF cells were isolated and differentiated as previ-
ously reported [23]. Conditioned media were obtained by
incubating the cells for 8 h with serum-free DMEM con-
taining 0.25% BSA after two washes with PBS. After the
incubation, mediumwas collected and centrifuged at 14,000 g
to remove cellular debris and placed onto recipient cells for
different times, as indicated, or analysed for cytokines and
growth factor content, as described below. For co-cultures,
8×104 MCF-7 cells were seeded in the upper chamber of a
transwell culture system (4 μm pore size, Costar plates, Corn-
ing Life Sciences, Lowell, MA, USA) in a complete medium.
The following day, the cells were incubated in serum-free
DMEM 0.25% BSA with or without adipocytes in the lower
chamber. Sodium oleate and sodium palmitate were dissolved
in NaOH at 100 mmol/l final concentration and conjugated
with 10% fatty acid-free BSA (as a physiological carrier) at a
molar ratio of 3:1 [24].
Cell proliferation and viability MCF-7 (1×105 cells/well)
and MDA-MB-231 (1×105 cells/well) cells were seeded
in six-well culture plates in a complete medium. The
following day, the cells were starved in serum-free
DMEM 0.25% BSA for 16 h and incubated with condi-
tioned media obtained as described above for different
times. Cell count was performed either by Bürker cham-
ber and with the TC10 Automated Cell Counter (Bio-Rad)
according to the manufacturer’s protocol. Sulforhodamine
assay or crystal violet staining were used for cell viability
determination [25, 26].
Flow cytometry MCF-7 cells were kept in the presence or in
the absence of serum or incubated with conditioned media,
as indicated. Cell cycle phases were then assayed by cyto-
metric analysis as previously described [27].
Cytokine and growth factor assay 3T3-L1 and human pre-
adipocyte and adipocyte conditioned media were screened
for the concentration of IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17,
eotaxin, granulocyte-colony stimulating factor (G-CSF),
granulocyte–macrophage colony stimulating factor (GM-
CSF), IFN-γ, keratinocyte-derived chemokine (KC)/IL-8,
monocyte chemoattractant protein 1 (MCP-1), macrophage
inflammatory protein 1-alpha/beta (MIP-1α, MIP-1β),
RANTES, TNF-α, platelet-derived growth factor (PDGF),
vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF) and IGF-1, using the Bio-Plex multi-
plex Mouse and Human Cytokine and Growth factor kits
(Bio-Rad) according to the manufacturer’s protocol.
Real-time RT-PCR analysis Total RNA was isolated from
3T3-L1 and human pre-adipocytes and adipocytes by using
the Rneasy Kit (Qiagen Sciences, Germantown, MD, USA)
according to the manufacturer’s instruction. For real-time
RT-PCR analysis, 1 μg cell RNA was reverse transcribed
using SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). PCRs were analysed using SYBR
Green mix (Invitrogen). Reactions were performed using
Platinum SYBRGreen Quantitative PCR Super-UDG using
an iCycler IQ multicolor Real-Time PCR Detection System
(Bio-Rad). All reactions were performed in triplicate and
β-actin was used as an internal standard. Primer sequences
used are described in electronic supplementary material
(ESM) Table 1.
Immunoblot procedure Total cell lysates were obtained and
separated by SDS-PAGE as previously described [27].
Phosphoprotein assay Protein lysates were prepared by us-
ing Cell lysis kit (Bio-Rad) and the presence of phosphory-
lated Akt/PKB, ERK, STAT3 and IGF-1R was detected by
Bio-Plex Phospho- Ser473 Akt1/PKB, Phospho-Thr202/
Tyr204 ERK, Phospho-Tyr705 STAT3 and Phospho-Tyr1131
IGF-1R Assay kits and the Phosphoprotein Testing Reagent
kit (Bio-Rad) according to the manufacturer’s protocol. The
total proteins for Akt1/PKB, ERK and STAT3 were tested
using the Bio-Plex 3-plex assay kit (Bio-Rad).
Statistical analysis Data were analysed with Statview soft-
ware (Abacus concepts) by one-factor analysis of variance.
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A p-value of less than 0.05 was considered statistically
significant.
Results
Adipocytes promote breast cancer cell survival We first
analysed the impact of adipocyte-secreted factors on breast
cancer cell growth, in comparison with factors released by
undifferentiated fibroblasts. Conditioned medium (CM) from
3T3-L1 adipocytes induced a time-dependent increase of cell
growth, which was significantly more effective than that in-
duced by CM from 3T3-L1 fibroblasts (Fig. 1a) and similar to
that observed for cells incubated with 10% FBS-medium
(Fig. 1a). Consistent results were obtained with the ERα-
negative MDA-MB-231 cells (Fig. 1b), suggesting that the
effect was independent of oestrogen release. To investigate
whether human adipocytes were as effective as murine cell
lines in promoting breast cancer cell growth, we obtained
adipose tissue from breast surgery. As shown in Fig. 1c, CM
from adipocytes, either differentiated from SVF or directly
isolated from mammary specimens, induced growth of MCF-
7 cells, by 1.5 fold and twofold, respectively, while CM from
undifferentiated SVF cells had no significant effect. Similar
data were also obtained with MDA-MB-231 cells (data not


















































































































































































































Fig. 1 Effect of adipocyte-released factors on breast cancer cell
growth. (a) Undifferentiated mouse 3T3-L1 cells or mature 3T3-L1
adipocytes were incubated with serum-free DMEM for 8 h. Media
were collected from undifferentiated 3T3-L1 cells and from mature
3T3-L1 adipocytes (respectively, 3T3-L1 CM [grey diamonds] and
Adipo 3T3-L1 CM [black squares]) and added to serum-starved
MCF-7 breast cancer cells for 6, 12, 24 and 48 h. As a control,
MCF-7 cells were also incubated with DMEM without serum supple-
mentation (DMEM-BSA [white triangles]) or with 10% FBS (DMEM
10% FBS [white circles]). The cells were then counted as described in
the Methods and the results reported as fold increase over basal (cell
count in DMEM-BSA). (b) 3T3-L1 CM and Adipo 3T3-L1 CM were
added to serum-starved MDA-MB-231 breast cancer cells for 24 h. As
a control, MDA-MB-231 cells were also incubated with DMEM-BSA
or with DMEM 10% FBS. Cells were then counted as described in the
Methods and the results reported as fold increase over basal (cell count
in DMEM-BSA). (c) Adipose-derived SVF, differentiated adipocytes
(hAdipo) or mature adipocytes (Isol. Adipo) isolated from breast
surgery (n012) were incubated with serum-free medium for 8 h. Media
were collected (CM) and added to serum-starved MCF-7 cells for 24 h.
As a control, MCF-7 cells were also incubated with medium without
serum supplementation (basal medium). Cells were then counted and
the results reported as fold increase over basal (cell count in basal
medium). (d) 3T3-L1 CM, Adipo 3T3-L1 CM, SVF CM and hAdipo
CM were added to serum-starved MCF-7 for 48 h. Cell viability was
then assessed by sulforhodamine assay as described in the Methods
and the results reported as percentage of viable cells compared with
cells in DMEM 10% FBS, considered as 100% viable cells. (e) MCF-7
cells were seeded in the upper chamber of a transwell culture system
with or without 3T3-L1, Adipo 3T3-L1, SVF or hAdipo in the lower
chamber and cell viability was determined by crystal violet staining as
described in the Methods. The results are reported as percentage of
stained cells. *p<0.05, **p<0.01, ***p<0.001 compared with basal;
†p<0.05; ††p<0.01 compared with 3T3-L1 or SVF CM. (f) MCF-7
cells were starved in serum-free DMEM for 18 h and incubated with
3T3-L1 CM, Adipo 3T3-L1 CM, SVF CM and hAdipo CM for 24 h.
Cells were stained with propidium iodide and the ratio of cells in sub-
G1 phase was determined by cytometric analysis, as described in the
Methods. *p<0.05, comparing indicated data For all the panels in the
figure, data in the graphs represent the mean ± SD of at least four
independent triplicate experiments
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cell viability was increased by 3T3-L1 and human mammary
adipocyte CM by 1.6 and 2.6 fold, respectively comparedwith
their undifferentiated precursors (Fig. 1d).
Again, when co-cultured with 3T3-L1 and human adipo-
cytes, MCF-7 displayed higher viability, comparable with
that observed for cells cultured in DMEM–10% FBS. A
much lower effect was observed when MCF-7 cells were
co-cultured with either 3T3-L1 fibroblasts or SVF undiffer-
entiated cells (Fig. 1e).
To further investigate whether growth-promoting action
was dependent on oestrogen release by mature adipocytes,
MCF-7 cells were incubated with mammary adipocyte CM
in the presence of 1 μmol/l Tamoxifen, a selective oestrogen
receptor antagonist (ESM Fig. 1). No significant effect was
elicited by tamoxifen on the adipocyte growth-promoting
action. Also, exposure of the cells to anti-leptin antibodies
did not change the effect of adipocyte CM on cancer cell
growth (ESM Fig. 1).
Moreover, incubation of MCF-7 cells with CM from
3T3-L1 fibroblasts only slightly decreased the number of
cell deaths induced by growth factor deprivation, reducing
the number of cells in sub-G1 phase by 25% (Fig. 1f).
Interestingly, cell death was substantially rescued by incu-
bation with CM from 3T3-L1 adipocytes, at levels similar to
those achieved with 10%FBS medium (Fig. 1f). Again, the
number of cell deaths was decreased following incubation
with CM from mammary adipocytes, and from undifferen-
tiated SVF cells (Fig. 1f), although the effect of the latter
CM was lower.
Adipocyte factors induce MAPK, PI3K and JAK/STAT acti-
vation in MCF-7 cells To gain further insight into the mo-
lecular mechanism by which adipocytes promote breast
cancer cell growth, we tested the ability of adipocyte con-
ditioned media to induce mitogen-activated protein kinase
(MAPK), phosphatidylinositol 3-kinase (PI3K) and JAK/
STAT activation. To this aim, MCF-7 cells were treated with
CM from 3T3-L1 or from mammary adipocytes for 12 h
(ESM Fig. 2). Western blot and phosphoprotein assay
revealed that CM induced the phosphorylation of ERK,
Akt and STAT3 (ESM Fig. 2).
Release of cytokines/chemokines and growth factors by 3T3-
L1 and human mammary adipocytes Based on the observed
induction of signalling pathways, we have screened for the
ability of 3T3-L1 and mammary adipocytes to release cyto-
kines/chemokines and growth factors. Both 3T3-L1 fibro-
blasts and undifferentiated SVF cells released detectable
amounts of IL-4, IL-6, IL-10, IFNγ, KC/IL-8, MIP-1β,
RANTES and TNF-α; MIP-1α was exclusively detected
in the medium of 3T3-L1 pre-adipocytes and not of human
SVF cells. However, the levels of KC/IL-8 and RANTES
were higher both in 3T3-L1 and human adipocytes,
compared with their respective precursors. Moreover, in-
creased levels of IL-6 and MIP-1β were detected in the
CM of human adipocytes while not in the CM of 3T3-L1
adipocytes.
We also screened for growth factor release and found that
VEGF, bFGF, PDGF and IGF-1 were detectable in both pre-
adipocytes and adipocytes. However, while there was no
significant difference in the content of PDGF and bFGF, the
amount of VEGF was significantly reduced in the CM of
both 3T3-L1 and human mammary adipocytes. At variance,
IGF-1 was about fivefold higher in the CM of differentiated
3T3-L1 and mammary adipocytes (Table 1).
Similar to protein levels in the conditioned media, Kc
(also known as Cxcl1)/IL-8, RANTES and IGF-1 mRNA
levels were higher by 5, 6 and 6.5 fold, and 4, 4.5 and 7.5
fold, respectively, in differentiated 3T3-L1 cells and in
human adipocytes, compared with their undifferentiated
counterparts (Fig. 2).
Glucose and fatty acids modify adipocyte growth-promoting
action Next, 3T3-L1 adipocytes were cultured for 24 h
either in 5.5 mmol/l glucose (LG, low glucose), a concen-
tration corresponding to normal fasting glucose levels in
humans, or in 25 mmol/l glucose (HG, high glucose),
corresponding to the regular culture condition for this cell
line, but resembling hyperglycaemia in humans. Moreover,
we added to culture media either 0.5 μmol/l oleate or
10 μmol/l palmitate, two major fatty acids whose plasma
levels are increased in dysmetabolic conditions. Media were
changed and cells were allowed to secrete factors into fresh-
ly added serum-free medium. After 8 h, media were collect-
ed and tested for the content of cytokines/chemokines and
growth factors. No significant change was detected for IL-4,
IL-6, IL-10, IFN-γ, MIP-1α, MIP-1β, TNF-α, PDGF,
bFGF and VEGF (data not shown). However, 3T3-L1 adi-
pocytes cultured in HG medium released significantly
higher levels of KC (Fig. 3a), RANTES (Fig. 3b) and
IGF-1 (Fig. 3c), compared with those cultured in LG medi-
um. Very similar results were obtained for IL-8 (Fig. 3d),
RANTES (Fig. 3e) and IGF-1 (Fig. 3f) in differentiated
mammary adipocytes. Interestingly, culturing 3T3-L1 and
human adipocytes with either oleate or palmitate in LG
medium was accompanied by a significant increase of KC/
IL-8, RANTES and IGF-1 (Fig. 3a–f).
We next addressed whether regulation of those
adipocyte-produced factors occurred at the transcriptional
level. Kc and Igf-1 mRNA levels were about twofold higher
in 3T3-L1 adipocytes cultured in HG medium compared
with LG medium (Fig. 4). Similarly, in differentiated human
adipocytes, both IL-8 and IGF-1 levels were higher in HG
medium than in LG medium. At variance, RANTES (also
known as CCL5) mRNA levels were comparable in HG and
LG media, both in 3T3-L1 and human adipocytes.
Diabetologia (2012) 55:2811–2822 2815
However, when oleate or palmitate were added to LG
medium, significant increases of RANTES and IGF-1 (also
known as IGF1) mRNA levels, while not of Kc/IL-8, were
observed both in 3T3-L1 and human adipocytes.
Thus, these data suggest that glucose may upregulate Kc/
IL-8 and IGF-1, while fatty acids may induce RANTES and
IGF-1 at mRNA levels.
Therefore, we tested whether glucose and fatty acids may
change the growth-promoting action of murine and human
adipocytes. To this end, MCF-7 cells were incubated for
24 h in the presence of either LG or HG conditioned media
from 3T3-L1 and human mammary adipocytes. Pre-
incubation of adipocytes (both 3T3-L1 and human) with
HG medium enhanced, by about twofold, their ability to
induce MCF-7 cell growth, compared with LG medium
(Fig. 5). Moreover, the presence of palmitate or oleate in
the LG medium (from both 3T3-L1 and human adipocytes)
significantly increased breast cancer cell growth (Fig. 5).
Induction of breast cancer cell growth by adipocytes from
lean and obese individuals SVF cells were isolated from
abdominal liposuctions carried out in lean (n010) and obese
(n010) individuals. These cells were differentiated into
mature adipocytes and conditioned media were collected
as previously described (see Methods). As for mammary-
derived specimens (see Fig. 1c), abdominal subcutaneous
differentiated adipocytes induced MCF-7 cell growth to a
larger extent, compared with undifferentiated SVF cells
(Fig. 6) from both lean and obese individuals. However,
CM from both undifferentiated SVF cells and differentiated
adipocytes obtained from obese individuals were signifi-
cantly more effective than those obtained from lean individ-
uals in inducing MCF-7 cell growth.
Again, as for mammary adipocytes, the release of IL-8,
RANTES and IGF-1 was more abundant in mature subcu-
taneous adipocytes, compared with their undifferentiated
Table 1 Adipocyte-released cytokines and growth factors
Cytokine/growth factor 3T3-L1 CM (pg/ml) Adipo 3T3-L1 CM (pg/ml) SVF CM (pg/ml) hAdipo CM (pg/ml)
IL-2 ND ND ND ND
IL-4 0.7±0.008 0.10±0.02 1.12±0.66 1.36±0.66
IL-6 23.6±1.13 22.37±3.47 2,705.58±541 5,005.06±1,200†
IL-10 3.70±0.86 15±2.6* 10.47±2.24 6.53±1.66†††
GM-CSF ND ND ND ND
IFN-γ 3.73±0.38 5.59±0.80 46.70±9.2 41.64±19.8
KC/IL-8 989.14±100.62 10,343.72±1,551.53* 2,975.59±300 15,647.85±190.2††
MIP-1α 226.31±18,27 280±22.32 ND ND
MIP-1β 10.33±1.53 11.4±2 3.37±1.02 25.88±9.01††
RANTES 1,960±235.2 4,770±524.7* 12.27±1.5 52.99±10††
TNF-α 143.54±18.66 162.88±25.92 1.54±0.80 2.17±1.10
PDGF ND ND 1.20±0.90 2.65±1.32
bFGF 200±18 660.70±2.67* 19.37±3.87 25.58±5.37
VEGF 11,479.20±1,262.71 4,682.46±607.71* 526.53±105.30 295.58±65.02††
IGF-1 79.37±0.88 334.37±40.41* 28.85±0.50 136.66±5.7††
Data represent the mean ± SD of at least four independent triplicate experiments. Supernatants from mouse 3T3-L1 pre-adipocytes (3T3-L1 CM),
3T3-L1 adipocytes (Adipo 3T3-L1 CM), human SVF (SVF CM) and differentiated adipocytes (hAdipo CM were collected for 8 h and tested by
using the Bio-Plex multiplex cytokine assay kit and the Bio-Plex multiplex growth factor assay kit as described in the Methods















































Fig. 2 Kc/IL-8, RANTES and IGF-1 expression in differentiated adi-
pocytes vs undifferentiated precursors. Undifferentiated 3T3-L1 and
SVF cells or mature 3T3-L1 and human adipocytes were tested for the
levels of mouse Kc, Rantes and Igf-1 mRNA, or of human IL-8,
RANTES and IGF-1 mRNA by real-time RT-PCR analysis, as de-
scribed in the Methods. Dark grey columns represent 3T3-L1 adipo-
cytes; light grey columns represent human adipocytes. Bars represent
the mean ± SD of four independent experiments and show the mRNA
levels in these cells relative to those in 3T3-L1/human adipocyte
precursor cells. *p<0.05, **p<0.01, ***p<0.001, in comparison with
the respective measurement in precursor cells
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counterparts (Table 2), both for lean and obese individuals.
No difference in IL-4, IL-8, IL-10, IFN-γ, MIP-1α, MIP-
1β, RANTES, TNF-α, PDGF, bFGF and VEGF content
was found in the media of SVF cells and mature adipocytes
from lean and obese individuals. Nevertheless, IL-6 and
IGF-1 were significantly more abundant in CM of obese
compared with lean adipocytes (Table 2). Moreover, only
IGF-1 levels were higher in SVF cells from obese individ-
uals than in those from lean individuals.
Effect of IGF-1 pathway inhibition on cell growth To ad-
dress the biological relevance of IGF-1 as an adipocyte-
derived growth-promoting factor, MCF-7 cells were treated
with HG CM in the presence of 10 μmol/l AG1024, a
specific inhibitor of IGF-1R kinase activity.
AG1024 almost completely prevented the effect of 3T3-
L1 CM on MCF-7 cell growth (Fig. 7a). Very similar results
were obtained for the prevention of the effect induced by
mammary (Fig. 7b) as well as subcutaneous abdominal
adipocytes, both from lean and from obese individuals
(Fig. 7c). Indeed, the induction of MCF-7 cell growth by
lean and obese adipocytes was reduced at comparable lev-
els, following treatment with AG1024 (Fig. 7c). Moreover,
the increased growth induced by SVF cells from obese
individuals was fully rescued by AG1024 (Fig. 7c) and
returned to levels similar to those achieved by SVF cells
from lean individuals. Similarly, conditioned media from
obese adipocytes induced IGF-1R phosphorylation twofold
more effectively than those from lean individuals (Fig. 7d).
Also, only SVF cells from obese, and not from lean, indi-
viduals were able to increase IGF-1R phosphorylation. Fi-
nally, these effects were completely blocked by AG1024,
indicating a major involvement of IGF-1 (Fig. 7d).
Discussion
Convincing evidence links obesity and diabetes to the risk
of several forms of cancer [4, 11, 14]. We now describe that
differentiated adipocytes, both of mouse and of human
origin, have a significant impact in enhancing breast cancer
cell survival and proliferation. Consistent with previous
reports [16], the effect of adipocytes is larger than that of
their precursor cells. Interestingly, however, their growth-
promoting action is paralleled by a specific secretory pattern
of inflammatory cytokines, chemokines and growth factors,
which is also affected by culture conditions. In particular,




























































































































































































































































Fig. 3 Effect of glucose and fatty acids on adipocyte-released cyto-
kines and growth factors. Mouse 3T3-L1 adipocytes (a–c) and human
adipocytes (d–f) were pre-incubated with high glucose DMEM
(25 mmol/l glucose, HG) or with low glucose DMEM (5.5 mmol/l
glucose, LG) for 24 h in the presence or absence of 10 μmol/l palmitate
(PAL) or 0.5 μmol/l oleate (OLE) for 18 h. They were then further
incubated with serum-free DMEM for 8 h. Media were collected (CM)
and tested by using the Bio-Plex multiplex cytokine assay kit and the
Bio-Plex multiplex growth factor assay kit. Values ± SD for mouse KC
(a), RANTES (b) and IGF-1 (c), and for human IL-8 (d), RANTES
(e) and IGF-1 (f) are reported in the bar graph *p<0.05, comparing
indicated data and represent the mean ± SD of at least four independent
triplicate experiments
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adipocytes to induce the growth of breast cancer cells. When
cultured in 25 mmol/l glucose (HG), a condition mimicking
hyperglycaemia, both 3T3-L1 and human breast mammary
adipocytes were more effective in inducing growth of MCF-7
and MDA-MB-231 cells, compared with when they were
cultured in 5.5 mmol/l glucose (LG), which represents normal
glycaemia in humans.
Incubation of adipocytes with fatty acids also led to in-
creased growth-promoting action, suggesting that metabolic
perturbations may change their secretory pattern. This effect
was observed with palmitate or oleate, either individually or in
combination (data not shown). Higher concentrations of fatty
acids (up to 100 μmol/l palmitate and 10 μmol/l oleate) had a
slightly higher effect on both cancer cell growth and secretory
profile (data not shown). Moreover, it is known that high
concentrations of fatty acids impair insulin sensitivity [28]
and this may further affect adipocyte functions.
It has been reported that adipocyte-derived molecules can
affect cancer cell growth. For instance, leptin has been
shown to induce proliferation of breast cancer cells [29].
However, we found that glucose and fatty acids had no
effect on leptin release by mammary adipocytes (data not
shown). Nevertheless, treatment of MCF-7 cells with anti-
leptin blocking antibodies did not rescue the effect of HG
adipocyte CM on cell growth (ESM Fig. 1). Adipocyte-
derived oestrogens have also been related to breast cancer
development and progression [30]. It seems unlikely that
oestrogens could mediate the effect of glucose and fatty
acids, however, since adipocyte CM elicited a similar effect
in the oestrogen-independent MDA-MB-231 cells and it
was unchanged following tamoxifen treatment of MCF-7
cells. We therefore tested whether glucose and fatty acids
could modify the release of cytokines, chemokines and
growth factors by adipocytes. The secretory patterns
obtained by mouse 3T3-L1 and human mammary adipo-
cytes were somewhat different. For example, MIP-1α and
TNF-α were more abundant in 3T3-L1 cells, while IL-6 and
IFN-γ were more abundant in human cells. However,
IL-8 and RANTES were released to a larger extent by
both differentiated 3T3-L1 cells and human adipocytes,
compared with their precursors, indicating that common
changes were present in the differentiation process. The
increased release of IL-8 and RANTES was paralleled
by a similarly sized increase in their mRNA levels.
Interestingly, both glucose and fatty acids increased the











































































































































































































































Fig. 4 Glucose and fatty acids control Kc/IL-8, RANTES and IGF-1
expression. Mouse 3T3-L1 adipocytes (a–c) and human adipocytes
(hAdipo) (d–f) were pre-incubated with either HG DMEM or with
LG DMEM for 24 h in the presence or absence of 10 μmol/l palmitate
(PAL) or 0.5 μmol/l oleate (OLE) for 18 h. Following this, mRNA
levels of mouse Kc (a), Rantes (b) and Igf-1 (c), and of human IL-8 (d),
RANTES (e) and IGF-1 (f) were determined by real-time RT-PCR
analysis. Data were normalized on β-actin as internal standard. Bars
represent the mean ± SD of four independent experiments and show the
mRNA levels in these cells relative to those in 3T3-L1/hAdipo HG
cells, reported as 1 in the first column of each bar graph. *p<0.05,
**p<0.01, comparing indicated data. Rel. expr., relative expression
2818 Diabetologia (2012) 55:2811–2822
environment could further modify adipocyte releasing prop-
erties. Similar results were also found for IGF-1, which was
more abundant in the medium of mature adipocytes and
upregulated by glucose and fatty acids. bFGF also tended
to be detected in higher amounts in the mature adipocytes,
while VEGF levels were more elevated in the undifferenti-
ated precursors. However, neither bFGF nor VEGF were
significantly regulated by nutrients.
We have obtained evidence that glucose and fatty acids
may regulate IL-8, RANTES and IGF-1 at different levels.
Culturing adipocytes in HG is accompanied by a significant
upregulation of IL-8 and IGF-1, while not of RANTES
mRNA, compared with low glucose. At variance, both
oleate and palmitate enhance IGF-1 and RANTES, while
not IL-8 mRNA levels. Altogether, these data raise the
possibility that, beside regulating gene expression, nutrients
may control adipocyte secretion process.
Thus, these findings are consistent with the hypothesis
that adipocytes, in an appropriate metabolic environment,
may contribute to tumour growth and progression by
releasing factors that may function to promote cancer cell
proliferation. In particular, RANTES, IL-8 and IGF-1 rep-
resent good candidates since: (1) they are produced in the
adipocytes and released in the culture medium; (2) their
production/release is induced by nutritional factors, such
as glucose and fatty acids; and (3) they have been implicated
in the control of cancer cell phenotypes. For instance,
RANTES and IL-8 are elevated in plasma of obese individ-
uals [31–33] and have been largely implicated in obesity-
related health complications [34–36] as well as in the mech-
anisms of cancer progression [37–39].
IGF-1 also plays a pivotal role in the progression of many
forms of cancer, including breast cancer [40–42]. Indeed IGF-1
is involved in the development of normal mammary gland and
in the onset and/or progression of mammary tumours [42], as
well as in the development of drug resistance [43].
It was recently reported that, in pancreatic cancer, auto-
crine production of IGF-1 by cancer cells enhances the
production of RANTES by stromal cells, thereby providing
a paracrine loop to facilitate tumour progression [44]. More-
over, expression profile studies indicate that IL-8 and IGF-1
are produced at higher levels in tissues from patients with
high-grade breast cancer than in tissues from patients with
low-grade breast cancer [45].
We have also found that adipocytes obtained from sub-
cutaneous fat specimens from obese individuals were capa-
ble of producing larger amounts of IGF-1 compared with
lean controls. This is consistent with higher circulating IGF-
1 levels often found in obesity [46]. Surprisingly, the differ-
ence was also significant when IGF-1 was measured in the
conditioned media of undifferentiated SVF cells from obese
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Fig. 5 Effect of glucose and fatty acids on adipocyte growth-
promoting action. Mouse 3T3-L1 adipocytes (a) and human adipocytes
(b) were pre-incubated with either HG DMEM or with LG DMEM for
24 h in the presence or absence of 10 μmol/l palmitate or 0.5 μmol/l
oleate for 18 h. They were then further incubated with serum-free DMEM
for 8 h. Media were collected (CM) and added to serum-starved MCF-7
cells for 24 h. Cells were then counted and the results reported as fold
increase over basal (cell count in DMEM-BSA). *p<0.05, **p<0.01,
comparing indicated data. Data in the bar graphs represent the mean ± SD































BMI 20−25 kg/m2 BMI 30−35 kg/m2
Fig. 6 Cancer cell growth induced by adipocytes from lean and obese
individuals. SVF cells and human adipocytes isolated from obese (BMI
30–35) and lean women (BMI 20–25) were incubated with serum-free
medium for 8 h. Media were collected (CM) and added to serum-
starved MCF-7 cells for 24 h. Then, cells were counted and the results
reported as fold increase over basal (cell count in medium without
serum supplementation). Dark grey columns represent SVF CM; light
grey columns represent human adipocyte (hAdipo) CM. *p<0.05,
comparing indicated data. Data in the bar graphs represent the mean
± SD of at least four independent triplicate experiments
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during adipocyte differentiation, is enhanced in obesity and
is maintained in cultured mesenchymal stem cells. This
could possibly be due to epigenetic changes in IGF-1 gene
expression regulation [47]. Interestingly, however, upregu-
lation was only observed for IGF-1 and not for other chemo-
kines and growth factors, both in undifferentiated SVF and
in mature adipocytes.
IGF-1 in the adipose tissue may act either as an autocrine
factor [48], regulating adipose tissue development and
homoeostasis, or in a paracrine manner, regulating survival
and function of the surrounding cells, including cancer cells.
Inhibition of IGF-1 function, indeed, almost completely
abolished the effect of adipocyte-released factors, thereby
indicating that IGF-1 is a pivotal factor in adipocyte
Table 2 Cytokines and growth factors released by adipocytes from lean and obese individuals
Cytokine/growth factor BMI 21–25 BMI 30–35
SVF CM (pg/ml) hAdipo CM (pg/ml) SVF CM (pg/ml) hAdipo CM (pg/ml)
IL-2 ND ND ND ND
IL-4 1.09±0.60 1.49±0.53 0.79±0.06 0.96±0.006
IL-6 2,446.87±489.37 6,420.31±1,348.26* 2,180.64±436.12 12,367.95±2,597.26*††
IL-10 11.40±2.66 6.75±1.48* 9.61±2.32 5.90±1.99*
GM-CSF ND ND ND ND
IFN-γ 45.82±9.62 46.7±10.27 38.86±12.72 41.64±18.80
IL-8 2,556.45±350.45 25,019.32±1,264.48** 1,229.32±380.12 22,271.66±5,308.75**
MIP-1α 58.82±7.98 136.23±9.62 54.14±4.80 52.95±7.83
MIP-1β 10.33±3.46 27.96±3.27* 3.52±0.58 34.62±8.44*
RANTES 17.98±3.40 73.65±9.68* 12.45±2.27 45.26±11.35**
TNF-α 204.08±15.35 291.65±35.82 173.49±18.52 200.04±21.71
PDGF 2.48±1.35 3.04±0.88 2.80±0.52 3.16±0.71
bFGF 28.63±11.90 36.88±12.66 14.68±3.74 24.55±6.27
VEGF 620.53±165.61 178.54±85.01** 483.06±29.48 322.20±71.55
IGF-1 115±54.46 666±40.42* 193.33±64.29† 1,073.33±22.30**†
SVF cells and differentiated SVF (hAdipo) isolated from obese (BMI 30–35; n010) and lean women (BMI 20–25; n010) were incubated with
serum-free medium for 8 h. Media were collected (CM) and analysed by using the Bio-Plex multiplex human cytokine assay kit and the Bio-Plex
multiplex human growth factor assay kit. Determinations were done in triplicate
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Fig. 7 Effect of IGF-1 pathway inhibition on cell growth. Conditioned
media collected from mouse 3T3-L1 adipocytes (a) and mammary
adipocytes (b) and subcutaneous abdominal SVF and adipocytes iso-
lated from obese (BMI 30–35) and lean women (BMI 20–25) (c) were
added to serum-starved MCF-7 cells for 24 h in the presence or
absence of 10 μmol/l AG1024. Cells were then counted and the results
reported as fold increase over basal (cell count in serum-free medium).
White columns, SVF CM; light grey columns, SVF CM + Ag1024;
dark grey columns, human adipocyte (hAdipo) CM; black columns,
hAdipo CM + Ag1024. (d) MCF-7 cells were exposed to conditioned
media collected from subcutaneous abdominal SVF and adipocytes
isolated from obese (BMI 30–35) and lean women (BMI 20–25) for
24 h and proteins extracted were tested for the presence of phosphor-
ylated IGF-1R by using the Bio-Plex phosphoprotein assay kit as
described in Methods. White columns, SVF CM; light grey columns,
SVF CM + Ag1024; dark grey columns, hAdipo CM; black columns,
hAdipo CM + Ag1024. *p<0.05, **p<0.01, comparing indicated data.
Data in the bar graphs represent the mean ± SD of at least four
independent triplicate experiments
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regulation of cancer cell growth. However, these results are
limited to breast cancer models, in which the importance of
the local environment, including adipocyte function, has
been largely documented. Further studies are needed to
assess the relevance of adipose-related factors in the control
of other cancer types. Moreover, the communications be-
tween cancer cells and adipocytes may be bidirectional.
Release of TNF-α from cancer cells may affect adipocyte
differentiation and function, possibly increasing NEFA re-
lease, to provide additional feed for the cancer cells [49, 50].
Thus, we have described that IGF-1 release by adipocytes
is enhanced in obesity and is regulated by metabolic pertur-
bations. Other factors, such as RANTES and IL-8, which are
not primarily upregulated in obese individuals, are also
enhanced by glucose and fatty acids and may as well con-
tribute to adipocyte control of breast cancer cell growth.
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